



MEMORANDUM

AntriaBio provides update on development plans, including delayed timeline for preclinical once-weekly basal insulin AB101 - November 13, 2015

AntriaBio provided an update on its pipeline and development plans, including a delay in the timeline for preclinical once-weekly basal insulin candidate AB101, in a recent [letter to shareholders](#). The letter noted that AntriaBio has completed all preclinical studies for AB101, including PK/PD studies in rats and dogs that support once-weekly dosing (presented at [ADA 2015](#)) and toxicity studies. The company now expects to file an Investigational New Drug application (IND) in 2Q16 and begin the first in-human trials of AB101 in 3Q16. This is a delay from the [previous expectation](#) of an IND filing in 2015 and the first in-human trials in 2H15. On the positive side, this latest update noted that the company has completed construction of a cGMP manufacturing suite and expects to manufacture clinical material in 4Q15 and 1Q16. The letter also highlighted AntriaBio's second pipeline candidate AB301, a preclinical once-weekly GLP-1 agonist/basal insulin for type 2 diabetes, which was first [announced](#) in September. Additional novel pipeline products will be announced in the next 12-18 months, and we certainly hope to see AntriaBio continue its focus on diabetes. Now that Sanofi has [licensed](#) Hanmi's portfolio of long-acting GLP-1 agonist and insulin candidates, we imagine that AntriaBio could be an appealing partner for Lilly or Novo Nordisk in the future, though that is very highly speculative at this point. [PhaseBio](#) also has a once-weekly basal insulin candidate in phase 2a and a once-weekly basal insulin/GLP-1 agonist combination in preclinical development.

-- by Helen Gao, Emily Regier, and Kelly Close